Using high-throughput proteomics, this study identified 34 differentially expressed proteins in the lesional skin of adults with scalp psoriasis, suggesting a cytokine storm response linked to bacterial antigens.
82 citations
,
June 2020 in “Inflammation Research” This review discusses the complex pathophysiological and clinical aspects of COVID-19, including dermatological findings and their association with SARS-CoV-2 infection but reports no new clinical results.
35 citations
,
November 2020 in “Dermatologic Therapy” This case series reports telogen effluvium in three patients following severe Sars-Cov-2 infection and suggests a potential association that merits further investigation.
185 citations
,
August 2020 in “Mayo Clinic Proceedings” This review discusses biological sex differences in COVID-19 outcomes and reports no new clinical results; it identifies a need for studies to clarify how sex influences disease progression.
25 citations
,
August 2021 in “Irish Journal of Medical Science (1971 -)” This study found that COVID-19 infection is a frequent cause of acute telogen effluvium, leading to excessive hair loss within 2–3 months after infection.
21 citations
,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” The researchers suggest that testosterone levels might influence COVID-19 susceptibility and severity, with low levels potentially protecting against infection but possibly worsening severe disease due to cytokine storm activation.
18 citations
,
April 2021 in “Experimental Dermatology” This study in Italy observed telogen effluvium and trichodynia as common hair-related complications following COVID-19 infection, raising questions about underlying hair follicle biology and potential receptor involvement.
7 citations
,
December 2021 in “Journal of The American Academy of Dermatology” This article discusses early-onset telogen effluvium following COVID-19 infection and reports no new results, encouraging further exploration into its pathogenesis and differences compared to other acute forms.
2 citations
,
July 2021 in “Dermatologic Therapy” This case study reports a 58-year-old woman experiencing pressure-induced alopecia with concomitant acute telogen effluvium after severe COVID-19, suggesting a potential link between prolonged hospitalization and hair loss.
1 citations
,
August 2022 in “Piel” This study found a statistically significant association between dermatological manifestations with vasculonecrotic damage and increased probability of severe COVID-19 disease among patients in Guatemala.
July 2023 in “Journal of the European Academy of Dermatology and Venereology” In a Phase II trial, Cox and colleagues reported that anti-IL17A therapy was well tolerated and led to a 64% reduction in wound size for venous leg ulcers unresponsive to standard treatments, although further validation in a larger trial is needed.
January 2023 in “International Journal of Dermatology and Venereology” This study found that a high percentage of patients reported experiencing hair loss following a COVID-19 infection, with more severe cases linked to more significant hair loss.
November 2022 in “Medicina” This case report describes post-COVID-19 telogen effluvium in a 39-year-old patient, suggesting that COVID-19 may trigger significant hair loss as a late symptom.
November 2022 in “DOAJ (DOAJ: Directory of Open Access Journals)” This case report describes a 39-year-old hypertensive and obese patient experiencing telogen effluvium potentially linked to a previous moderate COVID-19 infection, emphasizing the need for awareness of late symptoms associated with the disease.
April 2022 in “International journal of respiratory and pulmonary medicine” The authors propose that higher testosterone levels in hospitalized COVID-19 patients might be associated with worse outcomes.
17 citations
,
May 2022 in “Frontiers in Immunology” This review explores recent advances in inflammation resolution and considers how macrophage reprogramming might help address severe COVID-19 outcomes, particularly those involving cytokine storms, but it reports no new experimental results.
August 2023 in “Current Pharmaceutical Design” This review discusses the potential use of cannabidiol (CBD) for managing COVID-19 patients, especially for controlling cytokine storms in those with acute respiratory distress syndrome, but reports no new clinical results.
November 2025 in “The Journal of Dermatology” This study demonstrated that a mouse model of telogen effluvium induced by lipopolysaccharide was effective for evaluating the therapeutic effects of topical minoxidil, which accelerated hair regrowth in treated mice.
6 citations
,
March 2021 in “Cytotechnology” This review examines recent findings on COVID-19 pneumonia treatment using mesenchymal stem cells and reports no new clinical results; the authors highlight MSCs' potential due to their immunomodulatory and tissue-regenerative properties.
2 citations
,
November 2022 in “Zaporozhye Medical Journal” This review analyzes the wide range of extrapulmonary symptoms in COVID-19, highlighting variations in severity from mild cases with anosmia to severe cases impacting major organs.
122 citations
,
June 2020 in “Aging” This review discusses the hyperfunction theory of aging as a key factor in COVID-19 vulnerability, highlighting the potential of anti-aging interventions like rapamycin to reduce this risk.
19 citations
,
March 2022 in “Journal of Infection” This article discusses the withdrawal of bamlanivimab monotherapy's emergency use authorization in the U.S. due to evolving COVID-19 variants and offers no new clinical data.
6 citations
,
July 2021 in “Bulletin of the National Research Centre/Bulletin of the National Research Center” This review discusses the transmission and immune response of SARS-CoV-2 and highlights ongoing research for developing vaccines and antiviral treatments, but it presents no new clinical findings.
February 2025 in “Physician s Journal of Medicine” In this review, researchers highlighted that COVID-19 can cause various skin manifestations like maculopapular rashes and "COVID toes," which often precede or appear without respiratory symptoms, suggesting their potential for early detection and prognostic evaluation, especially in severe cases.
7 citations
,
January 2021 in “The journal of gene medicine” Certain genetic differences may affect how likely someone is to get COVID-19 and how severe it might be.
May 2026 in “AlQalam Journal of Medical and Applied Sciences” In this study, researchers found that relying solely on ferritin to assess iron status in young females with higher BMI may lead to inaccurate diagnoses of iron deficiency due to inflammation-related ferritin elevation.
3 citations
,
August 2025 in “Advanced Therapeutics” This review explores advancements in cytokine engineering for regenerative medicine, highlighting the development of modified cytokines with enhanced stability and tissue-targeting, potentially improving treatments for chronic wounds and fibrotic diseases by promoting tissue healing and minimizing inflammation, while adapting concepts from cancer immunotherapy.
March 2025 in “MAEDICA – a Journal of Clinical Medicine” This review explores the potential impact of SARS-CoV-2 on benign prostatic hyperplasia and related lower urinary tract symptoms but reports no new clinical results, emphasizing the need for further studies to quantify these changes.
139 citations
,
February 2010 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This review outlines the advancements in organ and tissue transplantation since the discovery of the human MHC and reports no new clinical results.
41 citations
,
September 1991 in “Medical hypotheses” This article reviews the potential role of prolactin as a neuroendocrine modulator in skin biology and pathology, discussing its relevance for conditions such as psoriasis and hair growth, but reports no new clinical findings.